By Mill Chart
Last update: Jan 28, 2025
Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if GENMAB A/S -SP ADR (NASDAQ:GMAB) is suited for growth investing, while it is forming a base and may be ready to breakout. Investors should of course do their own research, but we spotted GENMAB A/S -SP ADR showing up in our growth with base formation screen, so it may be worth spending some more time on it.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:GMAB was assigned a score of 8 for growth:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:GMAB, the assigned 7 for health provides valuable insights:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:GMAB has earned a 8 out of 10:
Besides the Technical Rating, ChartMill also assign a Setup Rating to every stock. This setup score also ranges from 0 to 10 and determines to which extend the stock is consolidating. This is achieved by evaluating multiple short term technical indicators. NASDAQ:GMAB currently has a 8 as setup rating:
GMAB has a bad technical rating, but it does show a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. There is a support zone below the current price at 20.45, a Stop Loss order could be placed below this zone.
Our Strong Growth screener lists more Strong Growth stocks and is updated daily.
Our latest full fundamental report of GMAB contains the most current fundamental analsysis.
Our latest full technical report of GMAB contains the most current technical analsysis.
This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
20.33
+0.15 (+0.74%)
Find more stocks in the Stock Screener
GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
GENMAB A/S (NASDAQ:GMAB) offers strong growth, profitability, and a reasonable valuation, making it a standout pick for GARP investors following Peter Lynch’s strategy.
GENMAB A/S -SP ADR is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:GMAB showcases decent financial health and profitability, coupled with an attractive price.